Author: Austin Nguyen; Julianne K David; Sean K Maden; Mary A Wood; Benjamin R Weeder; Abhinav Nellore; Reid F Thompson
Title: Human leukocyte antigen susceptibility map for SARS-CoV-2 Document date: 2020_3_26
ID: k3y8tpps_3
Snippet: While a detailed clinical picture of the COVID-19 pandemic continues to emerge, there remain substantial unanswered questions regarding the role of individual genetic variability in the immune response against SARS-CoV-2 (51). We hypothesize that individual HLA genotypes may differentially induce the T-cell mediated antiviral response, and could potentially alter the course of disease and its transmission. In this study, we performed a comprehens.....
Document: While a detailed clinical picture of the COVID-19 pandemic continues to emerge, there remain substantial unanswered questions regarding the role of individual genetic variability in the immune response against SARS-CoV-2 (51). We hypothesize that individual HLA genotypes may differentially induce the T-cell mediated antiviral response, and could potentially alter the course of disease and its transmission. In this study, we performed a comprehensive in silico analysis of viral peptide-MHC class I binding affinity , across 145 different HLA types , for the entire SARS-CoV-2 proteome.
Search related documents:
Co phrase search for related documents- immune response and pandemic clinical picture: 1, 2
- immune response and peptide mhc: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- immune response and peptide mhc class: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- immune response and potentially transmission disease course alter: 1
- immune response and SARS proteome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- immune response and silico analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- immune response and study comprehensive perform: 1
- immune response and transmission disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52
- immune response and transmission disease course: 1
- immune response and transmission disease course alter: 1
- individual genetic variability and peptide mhc: 1
- individual HLA genotype and peptide mhc: 1
- peptide mhc and SARS proteome: 1, 2, 3, 4
- peptide mhc and silico analysis: 1, 2, 3
- peptide mhc and viral peptide mhc class: 1, 2, 3
- peptide mhc and viral peptide mhc class silico analysis: 1, 2
- peptide mhc class and SARS proteome: 1, 2, 3
- peptide mhc class and silico analysis: 1, 2
- peptide mhc class and viral peptide mhc class: 1, 2, 3
Co phrase search for related documents, hyperlinks ordered by date